Roche Phase 3 Trial of New Lung Cancer Drug Meets Goal, Marking Another Step Forward for KRAS-Targeted Therapy
Divarasib has produced positive results in a pivotal clinical trial, bringing a new potential treatment option for a group of lung cancer patients with a specific KRAS mutation; however, before full data are released, the magnitude of efficacy, safety, and future regulatory path remain to be clarified.